Letter to the Editor: Reassessing intravenous antihypertensive choice in coronary artery disease-related hypertensive emergencies

doi:10.4330/wjc.118635

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(1)

(0)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article (XML)

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. Jul 26, 2026; 18(7): 118635
Published online Jul 26, 2026. doi: 10.4330/wjc.118635

Letter to the Editor: Reassessing intravenous antihypertensive choice in coronary artery disease-related hypertensive emergencies

Nikolaos Ktenopoulos, Nikias Milaras, Anastasios Apostolos, Konstantinos Tsioufis, Konstantinos Toutouzas, Skevos Sideris

Nikolaos Ktenopoulos, Nikias Milaras, Anastasios Apostolos, Konstantinos Tsioufis, Konstantinos Toutouzas, First Department of Cardiology, “Hippokration” General Hospital, National and Kapodistrian University of Athens, Athens 11527, Greece

Skevos Sideris, First Department of Cardiology, “Hippokration” General Hospital, Athens 11527, Greece

Author contributions: Ktenopoulos N and Milaras N contributed to the conceptualization and drafting of the manuscript; Apostolos A and Toutouzas K performed the literature search and provided critical revisions of the text; Tsioufis K and Sideris S provided senior oversight, supervised the project, and gave final approval for the version to be published.

Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.

Corresponding author: Nikias Milaras, MD, First Department of Cardiology, “Hippokration” General Hospital, National and Kapodistrian University of Athens, Vasilisis Sofias 14, Athens 11527, Greece. nikiasmilaras@gmail.com

Received: January 7, 2026
Revised: February 7, 2026
Accepted: April 13, 2026
Published online: July 26, 2026
Processing time: 191 Days and 16.9 Hours

Core Tip

Core Tip: Chaudhary et al provide large real-world evidence in coronary artery disease-associated hypertensive emergency comparing intravenous nitroglycerin with labetalol. Labetalol achieved target blood pressure faster, but nitroglycerin produced greater blood pressure reduction, fewer bradycardic events, smaller biomarker rises, shorter intensive care unit/hospital stays, and fewer 30-day readmissions. These results support phenotype-driven therapy, that labetalol when heart rate control is paramount, and nitroglycerin when ischemia, pulmonary congestion or myocardial injury risk dominate. Prospective validation is required before practice-changing recommendations.